A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives

Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
11/2007
11/22/2007	WO2007132873A1 Freeze-dried product for transferring nucleic acid, oligonucleic acid or derivative thereof
11/22/2007	WO2007132852A1 Poorly-water-soluble pharmaceutical agent
11/22/2007	WO2007132831A1 Method of producing s-adenosyl-l-methionine-containing dry yeast having excellent storage stability, the product thereof and composition for oral intake
11/22/2007	WO2007132790A1 Liposome having lipid membrane containing bacterial cell component
11/22/2007	WO2007132718A1 Solid preparation comprising adenosine 5'-triphosphate or physiologically acceptable salt thereof
11/22/2007	WO2007132710A1 Bactericidal/preservative agent
11/22/2007	WO2007132296A2 Multilayer tablet
11/22/2007	WO2007132207A2 Process for cross-linking moieties
11/22/2007	WO2007132205A2 Nanoparticle pharmaceutical carrier
11/22/2007	WO2007131972A1 Nicotine-carrier vaccine formulation
11/22/2007	WO2007131357A1 Pharmaceutical composition having reduced abuse potential
11/22/2007	WO2007107161A8 Lipid based drug delivery systems comprising phospholipase a2 degradable lipids that perform an intramolecular cyclization reaction upon hydrolysis
11/22/2007	WO2007103877A3 Pharmaceutical formulations of a monohydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
11/22/2007	WO2007100524A3 Repeat sequence protein polymer nanoparticles optionally containing active agents and their preparation
11/22/2007	WO2007071777A3 Immuno-rna-constructs
11/22/2007	WO2007011217A3 Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes
11/22/2007	WO2006115416A3 Liposomes
11/22/2007	WO2006107316A8 Improved formulations of fenofibrate containing menthol or peg/poloxamer
11/22/2007	WO2002047726A3 Pharmaceutical composition containing an active with a hemolytic action and a surfactant
11/22/2007	US20070270585 Cytotoxic agents comprising new maytansinoids
11/22/2007	US20070270503 Penetration of Active Substances Into Cells and Organs
11/22/2007	US20070270502 treatment of respiratory system disorders comprising administering non-surfactant aerosols comprising sodium chloride as a diluent and drugs selected from antibiotics, antihistamines and/or antiviral agents
11/22/2007	US20070270491 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
11/22/2007	US20070270379 Inclusion Complexes Containing Piroxicam, a Cyclodextrin and Arginine
11/22/2007	US20070270378 Viscous Agent for Ophthalmic Use
11/22/2007	US20070270334 Polypeptide-dimers for use in treatment and prevention of infection, bone, blood, eating, tumor, autoimmune and inflammatory disorders
11/22/2007	US20070269847 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer
11/22/2007	US20070269523 Carriers Comprising Colloidal Metal Praticles for Translocation into Cerberal Neurons
11/22/2007	US20070269517 Pharmaceutical Formulations for the Prolonged Release of Interferons and Their Therapeutic Applications
11/22/2007	US20070269505 Tamper Resistant Co-Extruded Dosage Form Containing An Active Agent And An Adverse Agent And Process Of Making Same
11/22/2007	US20070269504 Amphoteric liposomes
11/22/2007	US20070269496 Patch for Reducing Exposure of Skin to Ultraviolet Radiation
11/22/2007	US20070269491 Tooth whitening strips
11/22/2007	US20070269490 Material for Processed Food for Weight Reduction Diets and Weight Reduction Dietary Processed Food Using Thereof
11/22/2007	US20070269465 Anesthetic composition for topical administration comprising lidocaine, prilocaine and tetracaine
11/22/2007	US20070269447 Cytotoxic agents comprising new maytansinoids
11/22/2007	US20070269441 Immunoregulation in cancer, chronic inflammatory and autoimmune diseases
11/22/2007	US20070269430 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
11/22/2007	US20070269429 Treatment with anti-erbb2 antibodies
11/22/2007	US20070269428 Method for the Treatment of Multiple Sclerosis by Inhibiting Il-17 Activity
11/22/2007	US20070269417 Nicotine delivery systems
11/22/2007	US20070269415 Lotus extract and lactic acid bacterium active ingredients exhibit synergistic amelioration or treatment of allergic diseases including hay fever, bronchial asthma and dermatitis, such as atopic dermatitis; foods; reduced immunoglobulins (IgE);interleukin-4 inhibitor; tumor necrosis factor inhibitors
11/22/2007	US20070269407 Use of interleukin-19 to treat cervical cancer
11/22/2007	US20070269371 Antibodies with altered effector functions
11/22/2007	DE4140689B4 Inhalationspulver und Verfahren zu ihrer Herstellung Inhalable powders and methods for their preparation
11/22/2007	DE102006023365A1 Multiblockcopolymere mit Formgedächtniseigenschaften Multiblock copolymers having shape memory properties
11/22/2007	DE102006022866A1 Kohlenstoff-Granulat, Verfahren zu dessen Herstellung und dessen Verwendung Carbon granules, processes for its preparation and its use
11/22/2007	CA2652500A1 Coated pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent
11/22/2007	CA2652499A1 Pharmaceutical product for intraoral delivery of nicotine comprising trometamol as buffering agent
11/22/2007	CA2652475A1 Liposome having lipid membrane containing bacterial cell component
11/22/2007	CA2652280A1 Polymers for functional particles
11/22/2007	CA2652274A1 Il-1.alpha. immunization induces autoantibodies protective against atherosclerosis
11/22/2007	CA2651906A1 Methods and compositions relating to animal dietary acids
11/22/2007	CA2651283A1 Pulmonary delivery of 1.alpha.,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin
11/22/2007	CA2650237A1 Nicotine-carrier vaccine formulation
11/22/2007	CA2635767A1 Multilayer tablet
11/22/2007	CA2635011A1 Use of sialylated fusion polypeptides for inhibition of oculotropic viruses
11/21/2007	EP1857809A1 Method of measuring coating amount and method of estimating elution behavior
11/21/2007	EP1857494A1 Hydrogel for medical use
11/21/2007	EP1857489A1 Microparticle and pharmaceutical composition
11/21/2007	EP1857467A1 Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue
11/21/2007	EP1857462A1 Polyoxyalkylene derivative
11/21/2007	EP1857121A2 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
11/21/2007	EP1857120A1 Injection for mastitis
11/21/2007	EP1857115A2 Using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells
11/21/2007	EP1857114A1 Particle and preparation containing the particle
11/21/2007	EP1857112A1 Anticancer composition for oral use comprising liposome containing phytosterols and prevention or treatment for cancer using the liposome
11/21/2007	EP1857103A1 Transdermally absorbable preparation
11/21/2007	EP1857102A1 Folic acid supplement
11/21/2007	EP1857101A2 Medicaments
11/21/2007	EP1856179A2 Functionalized poly (ether-anhydride) block copolymers
11/21/2007	EP1856155A2 Monoclonal antibodies and immunodetection assay specific for the chemotactic epitope of the urokinase-type plasminogen activator receptor
11/21/2007	EP1856091A1 Compounds for stabilizing factor vii polypeptide formulations
11/21/2007	EP1855725A2 Cyclodextrin-based polymers containing photocleavable linkers for drug delivery
11/21/2007	EP1855724A2 Blys fusion proteins for targeting blys receptor and methods for treatment of b-cell proliferative disorders
11/21/2007	EP1855723A2 Targeted drug-carrying bacteriophages
11/21/2007	EP1855722A2 Compounds for stabilizing factor vii polypeptide formulations
11/21/2007	EP1855699A1 Light pharmaceutical water and therapeutic compositions and methods thereof
11/21/2007	EP1855669A1 Liposomal compositions for parenteral delivery of agents
11/21/2007	EP1855661A1 Formulation for aviptadil
11/21/2007	EP1855660A1 Non-fibrous transdermal therapeutic system and method for its production
11/21/2007	EP1855650A1 Aqueous topical gel of high stability based on metronidazole and method of preparation
11/21/2007	EP1718340B1 New effector conjugates, process for their production and their pharmaceutical use
11/21/2007	EP1711595B1 Use of polysulphated alginate in cellular matrices
11/21/2007	EP1670513A4 Use of cox-2 inhibitor to prevent t-cell anergy induced by dendritic cell therapy
11/21/2007	EP1543324B1 Methods and compositions for grafting functional loops into a protein
11/21/2007	EP1505975B1 Compositions and method for treating infection in cattle and swine
11/21/2007	EP1424997B1 Amino acid modulated extended release dosage form
11/21/2007	EP1423102B1 Plaster for the treatment of dysfunctions and disorders of nail growth
11/21/2007	EP1414497A4 Novel microemulsion and micelle systems for solubilizing drugs
11/21/2007	EP1301500B1 Nitrosated and nitrosylated taxanes, compositions and methods of use
11/21/2007	EP1296658B8 Use of an acetylated pre-gelled starch with a high content of amylose
11/21/2007	EP1261646B1 Gels of hyaluronic acid cross-linked with bi-functional l-aminoacids or l-aminoesters or mixtures thereof
11/21/2007	EP1188445B1 Drug composition containing lecithin-modified superoxide dismutase
11/21/2007	EP0981374B1 Sustained-release delayed gels
11/21/2007	CN101076354A Carrier used for medicine giving for intestine
11/21/2007	CN101076353A Releasable polymer conjugate based on aliphatic biodegradable joint
11/21/2007	CN101076344A Multi-purpose bio-material composition
11/21/2007	CN101076343A Use of A2A adenosine receptor agonists
11/21/2007	CN101075022A Flexible conea contact lenses with antibacterial performance, its production and use

1 ... 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 ... 1712